These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 22144567)

  • 1. Using stress testing to guide primary prevention of coronary heart disease among intermediate-risk patients: a cost-effectiveness analysis.
    Galper BZ; Moran A; Coxson PG; Pletcher MJ; Heidenreich P; Lazar LD; Rodondi N; Wang YC; Goldman L
    Circulation; 2012 Jan; 125(2):260-70. PubMed ID: 22144567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis.
    Pignone M; Earnshaw S; Tice JA; Pletcher MJ
    Ann Intern Med; 2006 Mar; 144(5):326-36. PubMed ID: 16520473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating the Impact and Cost-Effectiveness of Statin Use Guidelines for Primary Prevention of Coronary Heart Disease and Stroke.
    Heller DJ; Coxson PG; Penko J; Pletcher MJ; Goldman L; Odden MC; Kazi DS; Bibbins-Domingo K
    Circulation; 2017 Sep; 136(12):1087-1098. PubMed ID: 28687710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing impact and cost-effectiveness of primary prevention strategies for lipid-lowering.
    Pletcher MJ; Lazar L; Bibbins-Domingo K; Moran A; Rodondi N; Coxson P; Lightwood J; Williams L; Goldman L
    Ann Intern Med; 2009 Feb; 150(4):243-54. PubMed ID: 19221376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strategies for Primary Prevention of Coronary Heart Disease Based on Risk Stratification by the ACC/AHA Lipid Guidelines, ATP III Guidelines, Coronary Calcium Scoring, and C-Reactive Protein, and a Global Treat-All Strategy: A Comparative--Effectiveness Modeling Study.
    Galper BZ; Wang YC; Einstein AJ
    PLoS One; 2015; 10(9):e0138092. PubMed ID: 26422204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using the coronary artery calcium score to guide statin therapy: a cost-effectiveness analysis.
    Pletcher MJ; Pignone M; Earnshaw S; McDade C; Phillips KA; Auer R; Zablotska L; Greenland P
    Circ Cardiovasc Qual Outcomes; 2014 Mar; 7(2):276-84. PubMed ID: 24619318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of providing full drug coverage to increase medication adherence in post-myocardial infarction Medicare beneficiaries.
    Choudhry NK; Patrick AR; Antman EM; Avorn J; Shrank WH
    Circulation; 2008 Mar; 117(10):1261-8. PubMed ID: 18285564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Summaries for patients. The cost-effectiveness of aspirin, statins, or both drugs in the primary prevention of heart disease.
    Ann Intern Med; 2006 Mar; 144(5):I29. PubMed ID: 16520469
    [No Abstract]   [Full Text] [Related]  

  • 9. Cost-effectiveness of statin treatment for primary prevention in conditions of real-world adherence--estimates from the Finnish prescription register.
    Aarnio E; Korhonen MJ; Huupponen R; Martikainen J
    Atherosclerosis; 2015 Mar; 239(1):240-7. PubMed ID: 25618032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic analysis of treatments reducing coronary heart disease mortality in England and Wales, 2000-2010.
    Fidan D; Unal B; Critchley J; Capewell S
    QJM; 2007 May; 100(5):277-89. PubMed ID: 17449875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular Genetic Risk Testing for Targeting Statin Therapy in the Primary Prevention of Atherosclerotic Cardiovascular Disease: A Cost-Effectiveness Analysis.
    Jarmul J; Pletcher MJ; Hassmiller Lich K; Wheeler SB; Weinberger M; Avery CL; Jonas DE; Earnshaw S; Pignone M
    Circ Cardiovasc Qual Outcomes; 2018 Apr; 11(4):e004171. PubMed ID: 29650716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systematic review and economic evaluation of statins for the prevention of coronary events.
    Ward S; Lloyd Jones M; Pandor A; Holmes M; Ara R; Ryan A; Yeo W; Payne N
    Health Technol Assess; 2007 Apr; 11(14):1-160, iii-iv. PubMed ID: 17408535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Statins for cardiovascular prevention according to different strategies: a cost analysis.
    Ito MK; Nanchen D; Rodondi N; Paccaud F; Waeber G; Vollenweider P; Marques-Vidal P
    Am J Cardiovasc Drugs; 2011; 11(1):33-44. PubMed ID: 21265581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost effectiveness of statins for the secondary prevention of coronary heart disease in Ireland.
    Barry M; Heerey A
    Ir Med J; 2002 May; 95(5):133-5. PubMed ID: 12092692
    [No Abstract]   [Full Text] [Related]  

  • 15. [Primary prevention of coronary heart disease? What is cost effective in the clinical practice?].
    Kübler W
    Z Kardiol; 2005; 94 Suppl 3():III/92-9. PubMed ID: 16258799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of coronary artery calcium testing for coronary heart and cardiovascular disease risk prediction to guide statin allocation: the Multi-Ethnic Study of Atherosclerosis (MESA).
    Roberts ET; Horne A; Martin SS; Blaha MJ; Blankstein R; Budoff MJ; Sibley C; Polak JF; Frick KD; Blumenthal RS; Nasir K
    PLoS One; 2015; 10(3):e0116377. PubMed ID: 25786208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implications of Coronary Artery Calcium Testing for Treatment Decisions Among Statin Candidates According to the ACC/AHA Cholesterol Management Guidelines: A Cost-Effectiveness Analysis.
    Hong JC; Blankstein R; Shaw LJ; Padula WV; Arrieta A; Fialkow JA; Blumenthal RS; Blaha MJ; Krumholz HM; Nasir K
    JACC Cardiovasc Imaging; 2017 Aug; 10(8):938-952. PubMed ID: 28797417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease.
    Gaspoz JM; Coxson PG; Goldman PA; Williams LW; Kuntz KM; Hunink MG; Goldman L
    N Engl J Med; 2002 Jun; 346(23):1800-6. PubMed ID: 12050341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-utility of aspirin and proton pump inhibitors for primary prevention.
    Earnshaw SR; Scheiman J; Fendrick AM; McDade C; Pignone M
    Arch Intern Med; 2011 Feb; 171(3):218-25. PubMed ID: 21325111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of diagnostic strategies for patients with chest pain.
    Kuntz KM; Fleischmann KE; Hunink MG; Douglas PS
    Ann Intern Med; 1999 May; 130(9):709-18. PubMed ID: 10357689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.